tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Adnan Butt, 50 are a BUY (81.97%), 5 are a HOLD (8.2%), 6 are a SELL (9.84%).
Analyst Adnan Butt, carries an average stock price target met ratio of 69.58% that have a potential upside of 59.55% achieved within 512 days. Previously, Adnan Butt worked at GUGGENHEIM, RBC.
Adnan Butt’s has documented 131 price targets and ratings displayed on 12 stocks. The coverage was on the Healthcare sector.
Most recent stock forecast was given on REGN, Regeneron Pharmaceuticals at 22-Feb-2019.
Analyst best performing recommendations are on NBRV (NABRIVA THERAPEUTICS AG).
The best stock recommendation documented was for NBRV (NABRIVA THERAPEUTICS AG) at 11/12/2015. The price target of $5500 was fulfilled within 35 days with a profit of $54000 (90.76%) receiving and performance score of 25.93.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 26-Nov-2019
$85
$0.1 (0.12%)
$90
6 years 4 months 6 days ago
(26-Nov-2019)
1/5 (20%)
$1.12 (1.34%)
1338
Hold Since 25-Nov-2019
$85
$0.1 (0.12%)
$100
6 years 4 months 7 days ago
(25-Nov-2019)
1/5 (20%)
$1.25 (1.49%)
243
Buy Since 30-Nov-2017
$68
$-16.9 (-19.91%)
$68
6 years 4 months 7 days ago
(25-Nov-2019)
4/6 (66.67%)
$-15.75 (-18.81%)
235
Hold Since 17-Sep-2019
$59
$-25.9 (-30.51%)
$55
6 years 4 months 12 days ago
(20-Nov-2019)
8/9 (88.89%)
$-11.59 (-16.42%)
148
Buy Since 19-Apr-2017
$60
$-24.9 (-29.33%)
$55
6 years 5 months 1 days ago
(31-Oct-2019)
5/5 (100%)
$7.51 (14.31%)
205
What Year was the first public recommendation made by Adnan Butt?
